Sumitomo Mitsui Trust Group Inc. Acquires 45,623 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Posted by Trevor Kearing on Jan 13th, 2026

Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 7.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 700,673 shares of the pharmaceutical company’s stock after buying an additional 45,623 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.27% of Vertex Pharmaceuticals worth $274,412,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Lee Johnson Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $721,000. Police & Firemen s Retirement System of New Jersey grew its position in Vertex Pharmaceuticals by 3.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock worth $17,378,000 after buying an additional 1,393 shares in the last quarter. Bailard Inc. grew its position in Vertex Pharmaceuticals by 0.5% during the second quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock worth $16,983,000 after buying an additional 200 shares in the last quarter. SteelPeak Wealth LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth about $10,059,000. Finally, Moody Lynn & Lieberson LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.4% in the 2nd quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock valued at $25,856,000 after acquiring an additional 822 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

VRTX opened at $460.59 on Tuesday. The stock’s 50 day simple moving average is $444.19 and its 200 day simple moving average is $427.16. The firm has a market cap of $116.86 billion, a price-to-earnings ratio of 32.48 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm posted $4.38 earnings per share. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 63,781 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the completion of the sale, the chairman directly owned 24,026 shares in the company, valued at approximately $10,792,479.20. This represents a 72.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total value of $4,394,252.00. Following the transaction, the executive vice president owned 37,725 shares in the company, valued at approximately $17,391,225. This represents a 20.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 165,105 shares of company stock valued at $73,858,523 in the last quarter. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several recent analyst reports. Wells Fargo & Company boosted their price objective on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Scotiabank started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 price target for the company. Wolfe Research raised shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target on the stock in a report on Tuesday, January 6th. Leerink Partners lifted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a report on Monday, December 29th. Finally, Stifel Nicolaus cut their target price on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $503.80.

Check Out Our Latest Report on Vertex Pharmaceuticals

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

Positive Sentiment: Analysts note Vertex has a strong earnings-surprise history and the setup suggests another likely beat in the next quarterly report, which supports revenue and EPS upside expectations. Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
Positive Sentiment: Coverage of what drove Q4 performance highlights commercial execution and product momentum that underpin near-term revenue growth expectations. Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4
Positive Sentiment: Management provided pipeline and business updates ahead of investor meetings and the J.P. Morgan Healthcare Conference; the company framed 2025 as a foundation for continued growth and flagged 2026 milestones, which could boost investor confidence if execution continues. Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Neutral Sentiment: Reported short-interest data is anomalous (shows zero shares and NaN changes), producing no clear signal about bearish positioning or short pressure at this time; treat this as non-informative until corrected data is available.
Negative Sentiment: Insider selling: an EVP sold roughly $2.14M and another flagged sale of about $4.39M in separate filings; sizable insider sales can pressure sentiment even if they are routine or for diversification. Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $2,137,455.00 in Stock Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $4,394,252.00 in Stock

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.